9.65
-0.02 (-0.21%)
| Penutupan Terdahulu | 9.67 |
| Buka | 9.67 |
| Jumlah Dagangan | 10,818 |
| Purata Dagangan (3B) | 54,993 |
| Modal Pasaran | 209,337,440 |
| Harga / Buku (P/B) | 1.71 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| EPS Cair (TTM) | -1.28 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.48% |
| Nisbah Semasa (MRQ) | 25.86 |
| Aliran Tunai Operasi (OCF TTM) | -27.29 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.67 M |
| Pulangan Atas Aset (ROA TTM) | -15.91% |
| Pulangan Atas Ekuiti (ROE TTM) | -34.69% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Aardvark Therapeutics, Inc. | Menurun | - |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -5.0 |
| Osilator Teknikal | -0.5 |
| Purata | -1.13 |
|
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 14.22% |
| % Dimiliki oleh Institusi | 49.49% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Cormorant Asset Management, Lp | 30 Jun 2025 | 800,189 |
| Silverarc Capital Management, Llc | 30 Jun 2025 | 286,807 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 40.00 (HC Wainwright & Co., 314.51%) | Beli |
| Median | 29.50 (205.70%) | |
| Rendah | 19.00 (RBC Capital, 96.89%) | Beli |
| Purata | 29.50 (205.70%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 12.39 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 14 Aug 2025 | 19.00 (96.89%) | Beli | 11.26 |
| HC Wainwright & Co. | 30 Jun 2025 | 40.00 (314.51%) | Beli | 13.52 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |